ADIPONECTIN PEPTIDOMIMETICS FORMULATIONS
First Claim
Patent Images
1. A composition comprising:
- a therapeutically effective amount of a 1 kDa to 2 kDa peptide, a generally recognized as safe solubilizer, one or more generally recognized as safe surfactants, generally recognized as safe buffer, optionally boric acid and optionally mannitol;
wherein the osmolality is between 260 to 330 mOsm/kg and the pH is between 4.5 to 5.5.
1 Assignment
0 Petitions
Accused Products
Abstract
Disclosed are compositions and methods for the use of adiponectin peptidomimetics in therapeutic applications. The compositions can include a peptide, for example, D-Asn-Ile-Pro-Nva-Leu-Tyr-D-Ser-Phe-Ala-D-Ser-NH2, a solubilizer, a surfactant(s), a buffer, optionally boric acid and optionally mannitol. The osmolality of the composition can be between 260 to 330 mOsm/kg and the pH can be between 4.5 to 5.5. Methods of using the compositions in treating certain eye disease(s) are also disclosed.
-
Citations
15 Claims
-
1. A composition comprising:
- a therapeutically effective amount of a 1 kDa to 2 kDa peptide, a generally recognized as safe solubilizer, one or more generally recognized as safe surfactants, generally recognized as safe buffer, optionally boric acid and optionally mannitol;
wherein the osmolality is between 260 to 330 mOsm/kg and the pH is between 4.5 to 5.5.
- a therapeutically effective amount of a 1 kDa to 2 kDa peptide, a generally recognized as safe solubilizer, one or more generally recognized as safe surfactants, generally recognized as safe buffer, optionally boric acid and optionally mannitol;
-
2. A composition comprising:
- a therapeutically effective amount a 1 kDa to 2 kDa adiponectin peptidomimetic, a generally recognized as safe solubilizer, one or more a generally recognized as safe surfactants, a generally recognized as safe buffer, optionally boric acid and optionally mannitol;
wherein the osmolality is between 260 to 330 mOsm/kg and the pH is between 4.5 to 5.5. - View Dependent Claims (3, 4, 5, 6, 7, 8, 9, 10)
- a therapeutically effective amount a 1 kDa to 2 kDa adiponectin peptidomimetic, a generally recognized as safe solubilizer, one or more a generally recognized as safe surfactants, a generally recognized as safe buffer, optionally boric acid and optionally mannitol;
-
11. A method for treating a disease in a patient by administering to the patient a composition comprising:
- a therapeutically effective amount of a 1 kDa to 2 kDa peptide, a generally recognized as safe solubilizer, one or more generally recognized as safe surfactants, a generally recognized as safe buffer, optionally boric acid and optionally mannitol;
wherein the osmolality of the formulation is between 260 to 330 mOsm/kg and the pH is between 4.5 to 5.5. - View Dependent Claims (12, 13, 14, 15)
- a therapeutically effective amount of a 1 kDa to 2 kDa peptide, a generally recognized as safe solubilizer, one or more generally recognized as safe surfactants, a generally recognized as safe buffer, optionally boric acid and optionally mannitol;
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeAllysta Pharmaceuticals, Inc.
-
Original AssigneeAllysta Pharmaceuticals, Inc.
-
InventorsBarman, Shikha P, Ward, Kevin L, Chen, Yugang
-
Application NumberUS16/662,932Publication NumberTime in Patent OfficeDaysField of SearchUS Class CurrentCPC Class CodesA61K 38/10 Peptides having 12 to 20 am...A61K 38/22 Hormones derived from pro-o...A61K 47/10 Alcohols; Phenols; Salts th...A61K 47/12 Carboxylic acids; Salts or ...A61K 9/0048 Eye, e.g. artificial tearsA61K 9/08 Solutions composition of so...A61P 27/02 Ophthalmic agents
